Industry news

Share this article:
The FDA, in partnership with Duke University, announced the executive board for its Clinical Trials Transformation Initiative. The board will be co-chaired by Duke vice chancellor for clinical research Dr. Robert Califf and Dr. Rachel Behrman, director of the Office of Critical Path Programs at FDA. Industry representation on the board includes: Susan Alpert, SVP and chief quality and regulatory officer at Medtronic; Glenn Gormley, SVP, global clinical development and medical affairs, Novartis Pharmaceuticals; and Jay Siegel, group president, R&D, biotechnology, immunology and oncology at Johnson & Johnson. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions